How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,854 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling Full Text available with Trip Pro

Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling 27933205 2018 11 13 2056-5933 2 2 2016 RMD open RMD Open Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling. e000294 Meyer Alain A Centre de Référence des Maladies Auto-immunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Nouvel Hôpital Civil, Service des Explorations Fonctionnelles, Hôpitaux Universitaires de Strasbourg, Strasbourg

2016 RMD open

162. Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or Imiquimod generates a persistent humoral immune response that recognizes the bacterial surface Full Text available with Trip Pro

Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or Imiquimod generates a persistent humoral immune response that recognizes the bacterial surface The Ducreyi serum resistance A (DsrA) protein of Haemophilus ducreyi belongs to a large family of multifunctional outer membrane proteins termed trimeric autotransporter adhesins responsible for resistance to the bactericidal activity of human complement (serum resistance), agglutination and adhesion (...) and adjuvants on surrogates of protection. Our results indicate that a 20 μg dose of rNT-DsrA administered with alum elicited antisera with comparable bacterial surface reactivity to that obtained with complete/incomplete Freund's adjuvant. At that dose, high titers and bacterial surface reactivity persisted for 211 days after the first immunization. Administration of rNT-DsrA with CpG or imiquimod as adjuvants elicited a humoral response with similar quantity and quality of antibodies (Abs) as seen

2016 Vaccine

163. Topical imiquimod yields systemic effects due to unintended oral uptake Full Text available with Trip Pro

Topical imiquimod yields systemic effects due to unintended oral uptake Repetitive application of topical imiquimod is used as an experimental model for the induction of psoriasiform skin lesions in mice. The model is characterized by several inflammatory processes, including cytokine production both locally and systemically, cellular infiltration, and splenomegaly. To investigate the production of type I interferons in response to imiquimod-containing Aldara cream, IFNβ-luciferase reporter (...) mice were imaged in vivo and ex vivo. Type I interferons were found to be produced in the skin, but also in the intestinal system caused by unintended ingestion of imiquimod by the mice. Through the use of Elizabethan collars to prevent ingestion, these effects, including psoriasiform lesions were nearly completely prevented. Our findings reveal that topical treatment with Aldara induces a psoriasiform skin inflammation, but that its mode of action depends on ingestion of the chemical, which leads

2016 Scientific reports

164. Effects of Human Mesenchymal Stem Cells Transduced with Superoxide Dismutase on Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Full Text available with Trip Pro

Effects of Human Mesenchymal Stem Cells Transduced with Superoxide Dismutase on Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice The immunomodulatory and anti-inflammatory properties of mesenchymal stem cells (MSCs) have been proposed in several autoimmune diseases and successfully tested in animal models, but their contribution to psoriasis and underlying pathways remains elusive. Likewise, an increased or prolonged presence of reactive oxygen species and aberrant antioxidant systems (...) in skin are known to contribute to the development of psoriasis and therefore effective antioxidant therapy is highly required. We explored the feasibility of using extracellular superoxide dismutase (SOD3)-transduced allogeneic MSCs as a novel therapeutic approach in a mouse model of imiquimod (IMQ)-induced psoriasis-like inflammation and investigated the poorly understood underlying mechanism. In addition, the chronicity and late-phase response of inflammation were evaluated during continued

2016 Antioxidants & redox signaling

165. Heme oxygenase-1 induction attenuates imiquimod-induced psoriasiform inflammation by negative regulation of Stat3 signaling Full Text available with Trip Pro

Heme oxygenase-1 induction attenuates imiquimod-induced psoriasiform inflammation by negative regulation of Stat3 signaling Heme oxygenase-1 (HO-1), a stress-inducible protein with a potential anti-inflammatory effect, plays an important role in skin injury and wound healing. However, the function of HO-1 in cutaneous inflammatory diseases, such as psoriasis, remains unknown. The abnormal activation of Stat3, a known transcription factor that induces inflammation and regulates cell

2016 Scientific reports

166. Therapeutic Effects of Erythroid Differentiation Regulator 1 on Imiquimod-Induced Psoriasis-Like Skin Inflammation Full Text available with Trip Pro

Therapeutic Effects of Erythroid Differentiation Regulator 1 on Imiquimod-Induced Psoriasis-Like Skin Inflammation Psoriasis is a common skin disease accompanied by chronic inflammation. In previous studies, erythroid differentiation regulator 1 (ERDR1) was shown to have a negative correlation with proinflammatory cytokine IL-18. However, the role of ERDR1 in the inflammatory skin disease psoriasis has not been evaluated. In this study, to investigate the role of ERDR1 in psoriasis, recombinant

2016 International journal of molecular sciences

167. Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports Full Text available with Trip Pro

Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports Non-Hodgkin lymphomas are a heterogeneous group, which involve either B or T lymphocytes. The most used treatment is a chemotherapy regimen, which includes cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone combined with rituximab - a monoclonal antibody specific for CD20 - an antigen expressed on B lymphocyte membrane. Nonmelanoma skin cancers (...) are the most common forms in patients who have lymphomas.We reported the cases of two Caucasian men affected by non-Hodgkin disease, treated with chemotherapy and rituximab. After treatment, they both presented superficial basal cell carcinoma and we prescribed imiquimod 5 % cream. Unfortunately, the drug was not effective in either patient and the tumors were excised.We speculated about the effect of rituximab on B lymphocytes, on a particular population of T cells and on antigen-presenting dendritic

2016 Journal of medical case reports

168. Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma Full Text available with Trip Pro

Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma Merkel cell carcinoma (mcc) is a highly aggressive neuroendocrine tumour of the skin. Remission rates are high with chemotherapy in patients with metastasis, but without any improvement in overall survival. We present the case of a 90-year-old woman with facial mcc. After radiation and surgery, the mcc recurred with widespread cutaneous and regional lymph node metastases. The metastases were treated (...) with weekly intralesional injections of 1-2×10(6) IU interferon alfa-2a, accompanied by topical imiquimod 5% cream 3 times weekly. After partial regression, subcutaneous pegylated interferon alfa-2b was added at a dose of 30 μg weekly, which was then increased to 50 μg weekly. At 4 months after the start of immunotherapy, all cutaneous metastases and the intralesionally treated lymph node metastases receded. Interruption or reduction of systemic interferon application resulted in locoregional relapses

2016 Current Oncology

169. Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33 Full Text available with Trip Pro

Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33 Interleukin (IL)-33 is a dual cytokine with both an alarmin role and a T helper 2 cell (Th2)-like inducing effect. It is involved in the pathogenesis of rheumatoid arthritis (RA) and its models; we recently demonstrated that exogenous IL-33 could inhibit collagen-induced arthritis (CIA) in C57BL/6 mice. However, its pathophysiological role in RA is unclear. Indeed, mice deficient in the IL-33 (...) expression was analyzed by X-Gal staining in various mice compartments. Frequencies of CD4(+)FoxP3(+) regulatory T cells (Tregs) and Th1 and Th17 cells were evaluated by flow cytometry in WT and IL-33(-/-) mice. Bone resorption was studied by evaluating osteoclast activity on a synthetic mineral matrix. Psoriasis-like dermatitis was induced by application of imiquimod to the skin of mice.Severity of CIA was similar in IL-33(-/-) and WT littermates. Joints of IL-33(-/-) mice with CIA showed IL-33 promotor

2016 Arthritis research & therapy

170. Extramammary Paget disease of the perianal region: the potential role of imiquimod in achieving disease control Full Text available with Trip Pro

Extramammary Paget disease of the perianal region: the potential role of imiquimod in achieving disease control Extramammary Paget disease (EMPD) is a rare perineal neoplasia associated with a high rate of local recurrence. Surgical excision is the standard treatment; however, this has high rates of post-operative morbidity in combination with potentially mutilating results. Previous literature has demonstrated good response with imiquimod 5% cream in patients with vulval EMPD, yet its (...) effectiveness in primary perianal disease is unknown.We describe the case of a 40-year-old woman presenting with EMPD of the perianal region, providing detailed histological and pictoral evidence of its response to topical imiquimod 5% cream over a 16-week period, which initially resulted in remission prior to metastatic lymph node recurrence. This case demonstrates the potential for topical imiquimod cream to avoid major surgery and its associated complications in patients presenting with EMPD

2016 Journal of surgical case reports

171. Overexpression of Glucocorticoid-induced Leucine Zipper (GILZ) increases susceptibility to Imiquimod-induced psoriasis and involves cutaneous activation of TGF-β1 Full Text available with Trip Pro

Overexpression of Glucocorticoid-induced Leucine Zipper (GILZ) increases susceptibility to Imiquimod-induced psoriasis and involves cutaneous activation of TGF-β1 Psoriasis vulgaris is a chronic inflammatory skin disease affecting millions of people. Its pathophysiology is complex and involves a skin compartment with epidermal and immune cells which produce cytokines, e.g. belonging to the IL-23-Th17-cell axis. Glucocorticoids (GCs) are the most common therapeutics used in cutaneous (...) inflammatory disorders and GC-induced leucine zipper (GILZ) has emerged as a mediator of GCs due to its anti-inflammatory actions, theoretically lacking GC side-effects. We evaluated whether GILZ may provide a better therapeutic index in comparison to GCs during the onset and progression of psoriasis by generating and characterizing a mouse model with generalized overexpression of this protein (GILZ-Tg mice) and the imiquimod (IMQ) psoriasis model. Unexpectedly, in GILZ-Tg mice, the severity of IMQ-induced

2016 Scientific reports

172. Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent Manner Full Text available with Trip Pro

Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent Manner Generalized pustular psoriasis (GPP) is a severe form of psoriasis that can be caused by missense mutations in the interleukin-36 (IL-36) receptor antagonist. In addition to neutrophil rich skin inflammation, GPP patients typically also experience anorexia, fever, malaise, and pain. The imiquimod-induced skin inflammation mouse model has rapidly become a popular (...) comparisons of test groups was developed. Female mice were found to develop more severe disease than male mice. Furthermore, mice deficient in both IL-1R1 and IL-36α are nearly disease-free, while mice lacking only one of these inflammatory mediators have less severe disease than wild type mice. Hence, the imiquimod-induced skin inflammation mouse model recapitulates not only plaque psoriasis, but also the more severe symptoms, that is, anorexia, malaise, and pain, seen in GPP.

2016 Mediators of inflammation

173. The Use of Noninvasive Optical Coherence Tomography to Monitor the Treatment Progress of Vismodegib and Imiquimod 5% Cream in a Transplant Patient with Advanced Basal Cell Carcinoma of the Nose Full Text available with Trip Pro

The Use of Noninvasive Optical Coherence Tomography to Monitor the Treatment Progress of Vismodegib and Imiquimod 5% Cream in a Transplant Patient with Advanced Basal Cell Carcinoma of the Nose Immunosuppressed transplant recipients have increased risk for the development of basal cell carcinoma skin cancers. While oral vismodegib therapy has been successful in treating locally advanced basal cell tumors, few studies document its use and efficacy in organ transplant patients (...) . In this immunocompromised population, topical imiquimod 5% cream has been shown to be an effective and well-tolerated option for superficial and nodular basal cell carcinomas. To the authors' knowledge, no data documents the use of optical coherence tomography, a noninvasive imaging technique, to monitor progress of such combined therapies on in vivo skin. The authors report the successful treatment of an extensive basal cell carcinoma on the nose of an immunosuppressed 54-year-old Caucasian man with a history

2016 The Journal of clinical and aesthetic dermatology

174. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases Full Text available with Trip Pro

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases Infiltration of cancers by T cells is associated with improved patient survival and response to immune therapies; however, optimal approaches to induce T cell infiltration of tumors are not known. This study was designed to assess whether topical treatment of melanoma metastases with the TLR7 agonist imiquimod plus administration of a multipeptide cancer (...) vaccine will improve immune cell infiltration of melanoma metastases.Eligible patients were immunized with a vaccine comprised of 12 melanoma peptides and a tetanus toxoid-derived helper peptide, and imiquimod was applied topically to metastatic tumors daily. Adverse events were recorded, and effects on the tumor microenvironment were evaluated from sequential tumor biopsies. T cell responses were assessed by IFNγ ELIspot assay and T cell tetramer staining. Patient tumors were evaluated for immune

2016 Cancer immunology, immunotherapy : CII

175. Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream Full Text available with Trip Pro

Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream 27051847 2016 04 07 2019 02 26 2352-5126 2 2 2016 Mar JAAD case reports JAAD Case Rep Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream. 114-6 10.1016/j.jdcr.2016.01.004 Leventhal Jonathan S JS Yale University School of Medicine, Department of Dermatology, New Haven, Connecticut (...) 2016 03 04 United States JAAD Case Rep 101665210 2352-5126 IL-2, interleukin-2 imiquimod immunotherapy interleukin-2 medical dermatology melanoma oncology 2016 4 7 6 0 2016 4 7 6 0 2016 4 7 6 1 epublish 27051847 10.1016/j.jdcr.2016.01.004 S2352-5126(16)00007-2 PMC4810288 Immunotherapy. 2011 May;3(5):653-71 21554094 J Immunol. 2005 Feb 1;174(3):1259-68 15661881 J Am Acad Dermatol. 2015 Oct;73(4):645-54 26259990 Cancer Immunol Immunother. 2011 Apr;60(4):487-93 21174093 Arch Dermatol. 2012 May;148(5

2016 JAAD Case Reports

176. Imiquimod-induced CCR9 Ameliorates murine TNBS Colitis Full Text available with Trip Pro

Imiquimod-induced CCR9 Ameliorates murine TNBS Colitis To investigate whether Imiquimod (IMQ) as TLR7 ligand protects mice from colonic inflammation and the mechanisms underlying in such immunoregulatory conditions. METHODS: Murine colitis was induced to Balb/c mice by administration of trinitrobenzene sulfonic acid (TNBS) with or without daily intraperitoneal administration of IMQ. Colitis was evaluated by body weight decreases and by histological score. Also colonic mRNA expression

2016 Fukushima journal of medical science

177. Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol

Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol (TopIC-2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02669459 Recruitment Status : Recruiting First Posted : February 1, 2016 Last Update Posted

2016 Clinical Trials

178. Imiquimod and Influenza Vaccine for Immunocompromised Patients

Imiquimod and Influenza Vaccine for Immunocompromised Patients Imiquimod and Influenza Vaccine for Immunocompromised Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Imiquimod and Influenza Vaccine (...) of Lausanne Hospitals Study Details Study Description Go to Brief Summary: In this open label, single centre, pilot randomized controlled clinical trial the investigators aim to compare the immunogenicity and safety of a new influenza vaccination strategy consisting in the topical administration of imiquimod at the injection site before vaccination vs. a standard intramuscular vaccine injection in SOT recipients and HIV-infected individuals. The investigators planned to enroll 70 outpatients patients (50

2016 Clinical Trials

179. [Evidence-based medicine: Analysis of the randomized trial "imiquimod vs. surgery for basal cell carcinoma"]. (Abstract)

[Evidence-based medicine: Analysis of the randomized trial "imiquimod vs. surgery for basal cell carcinoma"]. 25749512 2016 05 06 2018 12 02 0151-9638 142 5 2015 May Annales de dermatologie et de venereologie Ann Dermatol Venereol [Evidence-based medicine: Analysis of the randomized trial "imiquimod vs. surgery for basal cell carcinoma"]. 369-70 10.1016/j.annder.2015.01.008 S0151-9638(15)00012-5 Guillot B B Département de dermatologie, hôpital Saint-Eloi, CHU de Montpellier, rue A.-Fliche (...) , 34295 Montpellier cedex 5, France. Electronic address: b-guillot@chu-montpellier.fr. fre Journal Article Comment Médecine factuelle : analyse de l'essai randomisé « imiquimod versus chirurgie dans les carcinomes basocellulaires ». 2015 03 03 France Ann Dermatol Venereol 7702013 0151-9638 0 Aminoquinolines 0 Antineoplastic Agents IM Lancet Oncol. 2014 Jan;15(1):96-105 24332516 Aminoquinolines administration & dosage Antineoplastic Agents administration & dosage Carcinoma, Basal Cell drug therapy

2016 Annales de dermatologie et de venereologie Controlled trial quality: uncertain

180. Imiquimod Treatment of High-grade CIN

Imiquimod Treatment of High-grade CIN Imiquimod Treatment of High-grade CIN - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Imiquimod Treatment of High-grade CIN (TOPIC-3) The safety and scientific validity (...) Center Study Details Study Description Go to Brief Summary: This multi-center, open-label, non-randomized controlled intervention study aims to investigate the treatment efficacy, side-effects and quality of life associated with imiquimod treatment of high-grade CIN lesions, as an alternative to surgical treatment by Large Loop Excision of the Transformation Zone (LLETZ). Non-surgical treatment may prevent side-effects associated with surgical treatment, such as premature birth in subsequent

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>